Skip to main content

Identifying Patients

Open Up a World
FOR INDICATED UNCONTROLLED PATIENTS WITH MODERATE-TO-SEVERE ASTHMA

Look for the signs and symptoms of uncontrolled asthma and see how DUPIXENT can help your patients.

Open Up a World
FOR INDICATED UNCONTROLLED PATIENTS WITH MODERATE-TO-SEVERE ASTHMA

Look for the signs and symptoms of uncontrolled asthma and see how DUPIXENT can help your patients.

Signs and symptoms of
uncontrolled asthma1-3

 
  • Cough
  • Shortness of breath
  • Wheezing
  • Nighttime awakening due
    to asthma1
  • Frequent exacerbations
  • Impaired lung function
    (airflow limitations)
  • Frequent albuterol use
  • Activity limitation due to asthma1

DUPIXENT is indicated as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. Limitations of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.

Help appropriate patients benefit from the only dual inhibitor indicated in moderate-to-severe asthma2,3

Patient profiles are representative and are not actual DUPIXENT patients.

Uncontrolled asthma patient with elevated EOS, a marker of type 2 inflammation1

Patient
complaints

  • Limits outdoor activities due to fear
    of exacerbations
  • Exhausted by frequent urgent
    care visits due to asthma attacks
  • Misses out on some of her
    child’s activities due to
    shortness of breath

Diagnostic/Clinical findings

  • Elevated blood EOS ≥150 cells/μL
  • Reduced lung function (percent predicted FEV1: 64%)
  • On ICS/LABA
  • Frequent use of albuterol
  • May also have:
    • Elevated FeNO
    • Elevated IgE
    • Childhood history of asthma
SEE THE EXACERBATION REDUCTION DATA SEE THE LUNG FUNCTION IMPROVEMENT DATA

Uncontrolled asthma patient with type 2 inflammation requiring multiple OCS bursts

Patient
complaints

  • Shortness of breath restricts him from being physically active despite albuterol use
  • Frustrated with recent weight gain and sleep disturbance due to frequent OCS use
  • Tired of missing family events due to asthma attacks

Diagnostic/Clinical findings

  • Multiple OCS bursts this year
  • Recent history of elevated EOS
SEE THE OCS REDUCTION DATA

Child with uncontrolled asthma and elevated EOS, a marker of type 2 inflammation1

Patient
complaints

  • Difficulty keeping up with her friends at recess because she cannot catch her breath
  • Her parents are afraid she might experience an asthma attack while on a field trip
  • Her parents want to limit SCS use when possible because of potential side effects

Diagnostic/Clinical findings

  • Elevated EOS: ≥150 cells/μL
  • Reduced lung function (percent predicted FEV1: 74%)
  • On ICS/LABA
  • May also have:
    • Elevated FeNO
    • Elevated IgE
    • History of allergic rhinitis
See the pediatric data

EOS, eosinophils; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; OCS, oral corticosteroid; SCS, systemic corticosteroid.

SEE THE RESULTS OF DUPIXENT

Get More Information
on the Clinical Trials

SEE THE FULL STUDY DESIGNS